Started production of plasmid for mRNA synthesis of spike protein derived from Palmcad Omicron
Igene Co., Ltd., which is developing an mRNA-based COVID-19 prevention vaccine ‘EG-COVID’, has started developing an mRNA-based vaccine that can respond to the Omicron mutated virus.
An official from Igene said, “Omicron mutation includes mutations such as D614G, N501Y, and K417N that have a great effect on virus infection, so it is predicted that the infectivity will be higher than other mutated viruses. In addition, there are still no sufficient data on the severity of progression and no studies on the protective ability of existing vaccines, so concerns about the spread are growing.”
He also explained, “It is the common opinion of expert researchers that existing vaccines are unlikely to be effective against the omicron mutant virus, and accordingly, global pharmaceutical companies are planning to develop new vaccines rather than existing vaccines.”
Igene also decided that the development of a new mRNA-based vaccine would be a more effective response to the omicron-mutated virus. together with the development of a new vaccine.
A representative of Igene said, “Currently, Palmcad analyzed the mRNA sequence of the Omicron mutant virus and provided Igene with information on candidate substances with secured thermodynamic stability. We started making plasmids for When the plasmid production is completed, the company plans to conduct research on a new vaccine that can respond to the omicron-mutated virus in earnest. Based on our experience in research on ‘EG-COVID’, we will aim for rapid clinical entry.”
.
